We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Coil Embolization of Coronary Artery Fistulas

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00198016
First Posted: September 20, 2005
Last Update Posted: October 17, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
HOSPITEN
  Purpose
Background and Purpose: Congenital coronary artery fistula (CAF) is an uncommon anomaly. In some patients they can became symptomatic, associated with significant morbidity and mortality. We report our experience in percutaneous treatment of CAF.

Condition Intervention Phase
C14 C14907933 C14907933125 G09330582163324 C14280647250 Device: Coil Phase 4

Study Type: Observational
Official Title: Coil Embolization of Coronary Artery Fistulas: A Single Centre Experience

Resource links provided by NLM:


Further study details as provided by HOSPITEN:

Study Start Date: January 2004
Estimated Study Completion Date: August 2005
Detailed Description:

Congenital coronary artery fistula (CAF) can be defined as a direct communication of a coronary artery with a cardiac chamber, great vessel, or other vascular structure, bypassing the myocardial capillary bed.

CAF is an uncommon anomaly, occurring as an incidental finding in 0.1% to 0.2% of coronary angiograms. They are not gender specific. Many patients have symptoms like congestive heart failure, infective endocarditis, myocardial ischemia, or rupture of an aneurismal fistula. Surgical closure of coronary artery fistula was initially reported in 1983 with low rates of morbidity and mortality.

Percutaneous treatment appeared as an alternative to surgery. Transcatheter closure of CAF was first utilized in 1983. Along this years, with experience and improvements in catheterization equipment and occlusion devices, CAF occlusion have been successfully performed using microcoils.

We report our experience in using microcoils to percutaneous treatment of coronary fistulas.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Coronary artery fistulas
  • Clinical diagnosis of angina, myocardial infarction, left ventricular insufficiency, ventricular enlargement

Exclusion Criteria:

  • Age <18 or > 85 years
  • Cardiogenic shock _ severe ventricular enlargement
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00198016


Locations
Spain
HOSPITEN
Santa Cruz, Tenerife, Spain, 38001
Sponsors and Collaborators
HOSPITEN
Investigators
Study Director: Zuheir Kabbani, Cardiology HOSPITEN
  More Information

ClinicalTrials.gov Identifier: NCT00198016     History of Changes
Other Study ID Numbers: HOSPITEN
First Submitted: September 12, 2005
First Posted: September 20, 2005
Last Update Posted: October 17, 2008
Last Verified: August 2005

Keywords provided by HOSPITEN:
coronary fistulas.
coils embolization.

Additional relevant MeSH terms:
Fistula
Pathological Conditions, Anatomical